Marcelo Hernández-Mora MD , René Arredondo-Hernández PhD , Carmen A. Castañeda-Camacho MD , Pamela X. Cervantes-Gutierrez MD , Gonzalo Castillo-Rojas PhD , Samuel Ponce de León MD , Yolanda López-Vidal PhD
{"title":"在活跃的大学生群体中开展的 \"2019 年科罗纳病毒病后效应 \"研究:一所大型教育机构的校内横断面研究","authors":"Marcelo Hernández-Mora MD , René Arredondo-Hernández PhD , Carmen A. Castañeda-Camacho MD , Pamela X. Cervantes-Gutierrez MD , Gonzalo Castillo-Rojas PhD , Samuel Ponce de León MD , Yolanda López-Vidal PhD","doi":"10.1016/j.mayocpiqo.2024.09.004","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate the associations among post-coronavirus disease 2019 (COVID-19) prevalence; risk factors and comorbidities have not been firmly established within a university outpatient population.</div></div><div><h3>Patients and Methods</h3><div>Records from 881 COVID-19 outpatient patients (504 females [57.9%] and 366 males [42.07%]), most of whom were between 30 and 40 years of age (mean=37.3 years old; 95% CI, 36.5-38.2), with initial infection data from February 2020 to August 2022 were reviewed once, whereas the survey took place during 2 different moments during the pandemic. The first period (April 20, 2021, to June 21, 2021) yielded 279 responses, whereas in the second period (June 23, 2021, to October 4, 2021), 602 responses were recorded. The instrument used contained 20 questions across 3 main domains: general information, data related to infection and adverse effects, and service satisfaction experience.</div></div><div><h3>Results</h3><div>All the patients were positive for immunoglobulin G antibodies against nucleocapsid by the third week. Post-COVID-19 symptoms arose at least 2 weeks after recovery from the initial illness; 654 individuals reported at least one symptom after the acute COVID-19 period, for a post-COVID-19 prevalence of 74.96%. The most frequent symptoms were fatigue (84%), headache (71%), and difficulty concentrating (71%). More than 60% of participants reported at least one comorbidity, among which the most common ones were obesity (35.9%), smoking (17.5%), and hypertension (12.2%).</div></div><div><h3>Conclusion</h3><div>In this study, we assessed post-COVID-19 prevalence among outpatients and found that comorbidities were strongly related to consequences impacting quality of life and mental health burden.</div></div>","PeriodicalId":94132,"journal":{"name":"Mayo Clinic proceedings. Innovations, quality & outcomes","volume":"8 6","pages":"Pages 521-529"},"PeriodicalIF":0.0000,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Post-Coronavirus Disease 2019 Effects in an Active University Population: A Within-Campus Cross-Sectional Study at a Major Educational Institution\",\"authors\":\"Marcelo Hernández-Mora MD , René Arredondo-Hernández PhD , Carmen A. Castañeda-Camacho MD , Pamela X. Cervantes-Gutierrez MD , Gonzalo Castillo-Rojas PhD , Samuel Ponce de León MD , Yolanda López-Vidal PhD\",\"doi\":\"10.1016/j.mayocpiqo.2024.09.004\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective</h3><div>To evaluate the associations among post-coronavirus disease 2019 (COVID-19) prevalence; risk factors and comorbidities have not been firmly established within a university outpatient population.</div></div><div><h3>Patients and Methods</h3><div>Records from 881 COVID-19 outpatient patients (504 females [57.9%] and 366 males [42.07%]), most of whom were between 30 and 40 years of age (mean=37.3 years old; 95% CI, 36.5-38.2), with initial infection data from February 2020 to August 2022 were reviewed once, whereas the survey took place during 2 different moments during the pandemic. The first period (April 20, 2021, to June 21, 2021) yielded 279 responses, whereas in the second period (June 23, 2021, to October 4, 2021), 602 responses were recorded. The instrument used contained 20 questions across 3 main domains: general information, data related to infection and adverse effects, and service satisfaction experience.</div></div><div><h3>Results</h3><div>All the patients were positive for immunoglobulin G antibodies against nucleocapsid by the third week. Post-COVID-19 symptoms arose at least 2 weeks after recovery from the initial illness; 654 individuals reported at least one symptom after the acute COVID-19 period, for a post-COVID-19 prevalence of 74.96%. The most frequent symptoms were fatigue (84%), headache (71%), and difficulty concentrating (71%). More than 60% of participants reported at least one comorbidity, among which the most common ones were obesity (35.9%), smoking (17.5%), and hypertension (12.2%).</div></div><div><h3>Conclusion</h3><div>In this study, we assessed post-COVID-19 prevalence among outpatients and found that comorbidities were strongly related to consequences impacting quality of life and mental health burden.</div></div>\",\"PeriodicalId\":94132,\"journal\":{\"name\":\"Mayo Clinic proceedings. Innovations, quality & outcomes\",\"volume\":\"8 6\",\"pages\":\"Pages 521-529\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-11-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Mayo Clinic proceedings. Innovations, quality & outcomes\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2542454824000651\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Mayo Clinic proceedings. Innovations, quality & outcomes","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2542454824000651","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Post-Coronavirus Disease 2019 Effects in an Active University Population: A Within-Campus Cross-Sectional Study at a Major Educational Institution
Objective
To evaluate the associations among post-coronavirus disease 2019 (COVID-19) prevalence; risk factors and comorbidities have not been firmly established within a university outpatient population.
Patients and Methods
Records from 881 COVID-19 outpatient patients (504 females [57.9%] and 366 males [42.07%]), most of whom were between 30 and 40 years of age (mean=37.3 years old; 95% CI, 36.5-38.2), with initial infection data from February 2020 to August 2022 were reviewed once, whereas the survey took place during 2 different moments during the pandemic. The first period (April 20, 2021, to June 21, 2021) yielded 279 responses, whereas in the second period (June 23, 2021, to October 4, 2021), 602 responses were recorded. The instrument used contained 20 questions across 3 main domains: general information, data related to infection and adverse effects, and service satisfaction experience.
Results
All the patients were positive for immunoglobulin G antibodies against nucleocapsid by the third week. Post-COVID-19 symptoms arose at least 2 weeks after recovery from the initial illness; 654 individuals reported at least one symptom after the acute COVID-19 period, for a post-COVID-19 prevalence of 74.96%. The most frequent symptoms were fatigue (84%), headache (71%), and difficulty concentrating (71%). More than 60% of participants reported at least one comorbidity, among which the most common ones were obesity (35.9%), smoking (17.5%), and hypertension (12.2%).
Conclusion
In this study, we assessed post-COVID-19 prevalence among outpatients and found that comorbidities were strongly related to consequences impacting quality of life and mental health burden.